Syngene International · tone and specificity signals across the available quarters.
Language signals
FY27 will be a transition year for Syngene with important leadership changes already underway to position this company for its next phase of growth, particularly in CDMO, biologics, and emerging AI enabled service lines.
We expect a broadly flat performance for FY27 while maintaining EBITDA margins in the mid-20s through disciplined cost management and sharper operational executions.
The Labrella headwinds have clearly had material impacts last year 26 and as we've outlined will continue to have effects through 27 and those are now absorbed in the guidance framework.